As Illumina disappoints Wall Street, competitors make their case at JPM
Last September, Illumina pledged to decipher a person’s genetic code for as little as $200 with its new sequencing machines, part of a wider push to make genetic testing a routine part of check-ups.
At the JP Morgan Healthcare Conference on Wednesday, competitor Element Biosciences said its technology could also sequence a genome for $200 – and potentially with machines that cost less.
“Our goal is to democratize sequencing by driving down costs,” said Element CEO Molly He.
Premium subscription required
Unlock this article along with other benefits by subscribing to one of our paid plans.